Michel Delforge
Overview
Explore the profile of Michel Delforge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
6094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka A, et al.
Future Oncol
. 2024 Apr;
20(18):1221-1235.
PMID: 38651976
No abstract available.
12.
Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, et al.
Lancet Haematol
. 2024 Feb;
11(3):e216-e227.
PMID: 38423700
Background: Chimeric antigen receptor T-cell therapy idecabtagene vicleucel (ide-cel) showed significantly improved progression-free survival compared with standard regimens in adults with relapsed and refractory multiple myeloma who had received two...
13.
Mateos M, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, et al.
Haematologica
. 2024 Feb;
109(7):2337-2340.
PMID: 38385280
No abstract available.
14.
Verbinnen M, Sprangers B, Abrahams A, Koshy P, van Kruijsdijk R, Philipse E, et al.
Nephrol Dial Transplant
. 2024 Jan;
39(5):888-892.
PMID: 38192041
No abstract available.
15.
Moreau P, Mateos M, Gonzalez Garcia M, Einsele H, De Stefano V, Karlin L, et al.
Adv Ther
. 2023 Dec;
41(2):696-715.
PMID: 38110653
Introduction: Teclistamab is the first approved B cell maturation antigen × CD3 bispecific antibody with precision dosing for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). We compared...
16.
Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, et al.
N Engl J Med
. 2023 Dec;
390(4):301-313.
PMID: 38084760
Background: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the...
17.
Martin T, Moreau P, Usmani S, Garfall A, Mateos M, San-Miguel J, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Dec;
24(3):194-202.
PMID: 38052709
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and...
18.
Avivi I, Vesole D, Davila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686635
Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational 'real-world' retrospective study analyzed the characteristics and outcomes of MM patients...
19.
Ramasamy K, Avet-Loiseau H, Blimark C, Delforge M, Gay F, Manier S, et al.
Hemasphere
. 2023 Sep;
7(9):e942.
PMID: 37663672
We used a modified Delphi approach to establish areas of consensus and nonconsensus regarding the utility of determining measurable residual disease (MRD) to assess multiple myeloma (MM) treatment response, which...
20.
Otero P, Towle K, Cope S, Caisip C, Davies F, Delforge M, et al.
Leuk Lymphoma
. 2023 Jul;
64(11):1864-1869.
PMID: 37497883
No abstract available.